Immuron CEO Steven Lydeamore Highlights Advances in Polyclonal Antibody Pipeline at TechKnow Invest Roadshow

Immuron’s Innovative Platform Technology Focused on Oral Polyclonal Antibodies

Immuron Limited is an Australian biopharmaceutical company dedicated to developing and commercializing orally delivered targeted polyclonal antibodies for infectious disease treatment. Its proprietary platform utilizes polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum, offering a unique therapeutic approach. This technology enables the production of highly specific immunoglobulins targeting virtually any enteric pathogen, with oral formulations such as tablets facilitating easy administration.

The platform’s scientific basis lies in the resilience of bovine immunoglobulin G (IgG), which withstands stomach acidity and digestive enzymes, remaining active throughout the gastrointestinal tract. This allows bovine IgG to directly target bacteria and pathogens in the gut, blocking viruses or bacteria at mucosal surfaces and neutralizing their toxins. This versatile technology supports the development of medicines for a broad range of infectious diseases.

TravelanAE: Commercial Success and Regulatory Approvals Across Regions

TravelanAE, Immuron’s flagship commercial product, applies its platform technology to prevent infectious diseases. It is an orally administered passive immunotherapy designed to reduce the risk of travelers’ diarrhea, a common digestive disorder caused by pathogenic bacteria and their toxins. TravelanAE is formulated as a purified tablet containing hyperimmune bovine antibodies that bind diarrhea-causing bacteria when taken with meals, preventing colonization and associated symptoms.

TravelanAE holds regulatory approvals in multiple jurisdictions: it is registered as a medicine in Australia (AUST L 106709) with indications to reduce travelers’ diarrhea risk and minor gastrointestinal disorders, licensed as a natural health product in Canada (NPN 80046016) for travelers’ diarrhea prevention, and marketed as a dietary supplement in the United States. This regulatory diversity reflects Immuron’s ability to maintain market presence globally.

IMM-124E: Development Using ETEC-Vaccinated Bovine Colostrum

IMM-124E, the active ingredient in TravelanAE, is produced from the colostrum of cattle immunized during pregnancy with a vaccine containing outer antigens from 13 human-derived enterotoxigenic Escherichia coli (ETEC) strains. This vaccination strategy generates high levels of antibodies targeting key ETEC surface antigens, including lipopolysaccharide, colonization factor antigen-I, and flagellin.

The hyperimmune colostrum exhibits strong binding and neutralizing activity against a broad range of lipopolysaccharide antigens from the 13 ETEC serotypes. IMM-124E is manufactured into tablets marketed as TravelanAE, representing a comprehensive approach to addressing multiple bacterial causes of travelers’ diarrhea.

Global Health Impact and Market Potential of Travelers’ Diarrhea

Travelers’ diarrhea is a significant health issue for international travelers and military personnel, making it a key clinical target for Immuron’s preventive therapies. Defined by frequent unformed stools plus symptoms such as nausea or abdominal cramps, it is the most common ailment among travelers to lower- and middle-income regions.

U.S. military personnel deployed abroad are particularly affected, with diarrheagenic E. coli, Campylobacter, and Shigella species as leading pathogens. This substantial disease burden highlights the commercial opportunity for effective prevention products like TravelanAE.

IMM-529: Investigational Therapy for Recurrent Clostridioides difficile Infection

Immuron is developing IMM-529 as an adjunctive oral therapy combined with standard antibiotics to prevent and treat recurrent Clostridioides difficile infection (CDI). IMM-529 antibodies target C. difficile to aid infection clearance and promote restoration of normal gut flora, addressing the challenge of disease recurrence.

In collaboration with Dr. Dena Lyras at Monash University, dairy cows are immunized to produce hyperimmune colostrum containing antibodies against three key C. difficile virulence factors: Toxin B, bacterial spores, and surface layer proteins of vegetative cells. This triple-target approach exemplifies sophisticated therapeutic design.

Pre-Clinical Efficacy of IMM-529 Across Disease Phases

IMM-529 has shown encouraging pre-clinical results in infection and relapse models. It demonstrated 80% efficacy in preventing primary disease (p=0.0052), 67% protection against recurrence (p<0.01), and 78.6% efficacy in treating primary disease with the Toxin B hyperimmune formulation (p<0.0001). These results cover prevention, treatment, and relapse phases of CDI.

Notably, IMM-529 antibodies cross-react with multiple human C. difficile strains, including hypervirulent types, suggesting broad strain coverage. Immuron assesses IMM-529 as the only investigational drug showing therapeutic potential across all three CDI disease phases, offering a differentiated approach to this high-burden infection.

ProIBSAE Distribution and Market Opportunity in Irritable Bowel Syndrome

Immuron holds exclusive distribution rights for ProIBSAE in Australia and New Zealand through Calmino group AB. ProIBSAE is a certified medical device designed to alleviate irritable bowel syndrome symptoms such as abdominal pain, bloating, and irregular bowel movements. It contains AVH200AE, derived from Aloe barbadensis Mill., which supports the intestinal mucosal barrier. ProIBSAE is safe for long-term use with no known drug interactions.

The market opportunity is significant, as irritable bowel syndrome affects roughly 30% of individuals, with higher prevalence in females. The Australian digestive remedies market was valued at approximately AU$221.14 million in 2025, growing at 3.28% annually. A usability study by Calmino involving 1,003 users found 94% reported benefits, 91% experienced improved daily life, and 98% would recommend ProIBSAE.

July 2026 TechKnow Invest Roadshow Presentation and Investor Outreach

On July 27, 2026, CEO Steven Lydeamore presented at the TechKnow Invest Roadshow at Sofitel Melbourne on Collins, outlining Immuron’s technology platform, commercial products, and pipeline development to investors and stakeholders. This engagement underscores the company’s focus on investor relations and capital markets communication.

The presentation detailed Immuron’s proprietary polyclonal immunoglobulin platform, TravelanAE’s market status, IMM-529’s development and pre-clinical data, and the ProIBSAE distribution partnership. By participating in this specialized technology and investment event, Immuron positioned itself as an innovative biopharmaceutical company to institutional investors. The presentation was authorized for release as an official company update.

Strategic Positioning in Infectious Disease and Gastrointestinal Therapeutics

Immuron’s diversified portfolio includes a commercial product with established market presence, an advanced investigational therapy addressing a critical unmet need, and a distributed product for chronic gastrointestinal symptoms. TravelanAE targets infectious diarrhea prevention in travelers, IMM-529 focuses on recurrent C. difficile infection treatment, and ProIBSAE addresses irritable bowel syndrome in Australia and New Zealand.

The company’s oral polyclonal antibody platform derived from engineered hyper-immune bovine colostrum supports development across numerous infectious disease indications, suggesting potential pipeline expansion beyond current programs. The CEO’s TechKnow Invest Roadshow presentation effectively communicated Immuron’s scientific innovation, regulatory achievements, and commercial prospects amid an active biopharmaceutical capital markets environment.